Mark Botti > Baker Botts L.L.P. > Washington DC, United States > Lawyer Profile
Baker Botts L.L.P. Offices

700 K Street, N.W.
Washington, D.C. 20001-5692
DISTRICT OF COLUMBIA
United States
- Firm Profile
- Go to...
Mark Botti

Work Department
Litigation / Antitrust
Position
Partner
Career
Mark Botti advises clients on the full spectrum of antitrust matters, including government investigations and litigation, mergers and acquisitions, joint ventures, private litigation, and competition policy matters. His work has spanned all sectors of the economy, including healthcare, managed care and health information technology; financial services, including electronic payment systems; intellectual property and high technology matters; forestry products; consumer products; national defense; media and entertainment; and insurance.
Currently Partner, Baker Botts; previously Chief, Litigation I Section, Antitrust Division, U.S. Department of Justice; Adjunct Associate Professor, American University Law School; Antitrust Practice Group Head and Head of Global Healthcare Industry Group with previous global law firms.
Memberships
Non-governmental advisor to the International Competition Network (ICN); Member, ABA Section of Antitrust Law, former leadership including Unilateral Conduct, Joint Conduct and Healthcare and Pharmaceutical Committees; District of Columbia Bar; U.S. Courts of Appeals for the Fourth and Sixth Circuits; District Courts for the District of Columbia and Northern District of Ohio.
Education
J.D. (cum laude), Case Western Reserve School of Law, 1985; A.B., Dartmouth College, 1982
Personal
https://www.linkedin.com/in/markjbotti1929
Top Tier Firm Rankings
- Energy > Energy litigation: electric power
- Energy > Energy litigation: oil and gas
- Energy > Energy transactions: electric power
- Energy > Energy transactions: oil and gas
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Dispute resolution > Corporate investigations and white-collar criminal defense
Firm Rankings
- Energy > Energy regulation: electric power
- Energy > Energy regulation: oil and gas
- Environment > Environment: litigation
- Environment > Environment: regulatory
- Intellectual property > Patents: licensing
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Energy > Renewable/alternative power
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Transport > Aviation and air travel: finance
- Finance > Capital markets: debt offerings
- Finance > Capital markets: equity offerings
- Finance > Capital markets: high-yield debt offerings
- Antitrust > Cartel
- Antitrust > Civil litigation/class actions: defense
- Tax > International tax
- Dispute resolution > M&A litigation: defense
- Antitrust > Merger control
- Intellectual property > Patents: litigation (full coverage)
- Intellectual property > Patents: litigation (International Trade Commission)
- Finance > Project finance
- Dispute resolution > Securities litigation: defense
- Media, technology and telecoms > Technology transactions
- Intellectual property > Trademarks: non-contentious (including prosecution, portfolio management and licensing)
- Tax > US taxes: contentious
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Commercial lending
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Labor and employment > ERISA litigation
- Dispute resolution > General commercial disputes
- Dispute resolution > International arbitration
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Tax > US taxes: non-contentious
- Real estate > Construction (including construction litigation)
- Healthcare > Life sciences
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Real estate > Real estate
- Finance > Restructuring (including bankruptcy): corporate
- Finance > Structured finance: securitization
- M&A/corporate and commercial > Venture capital and emerging companies